MARKET WIREYahoo Finance • 8h ago
Bicara Therapeutics (BCAX) Stock May Look Overvalued On Book ValueYahoo Finance report covering Bicara Therapeutics Inc. (BCAX) market action, institutional positioning, and fundamental catalysts.
Why BCAX Stock dropped -6.17% Today — RQD Quant Desk Flash
$9.13 -6.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $9.01
Bicara Therapeutics Inc. (BCAX) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $643.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BCAX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BCAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Bicara Therapeutics Inc. (NASDAQ: BCAX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $9.13 (-6.17% 1D, market cap $643.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BCAX ranks #842 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BCAX compare to OLMA and ABUS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BCAX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OLMA (Olema Pharmaceuticals Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -32.8%, cap $641.4M) and ABUS (Arbutus Biopharma Corporation) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $656.0M). Among the 5-stock peer group, BCAX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BCAX?
▼
Per BCAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002023658), Bicara Therapeutics Inc. generated $0 in revenue, -$137.9M in net income, and -$107.1M in free cash flow against $431.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $9.01 (-1.30%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BCAX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY BCAX SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (27% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$17.33+0.8% Next Q
38
Q2 (-2Q)Grade E$17.47-3.3% Next Q
35
Q3 (-1Q)Grade E$16.89-45.9% Next Q
33
CurrentGrade E$9.13-9.6% Hist 90D α
30
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BCAX Turnaround Squeeze
While BCAX currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.46) and Max Pain ($9.59) forces dealer call-delta covering toward $32.54.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BCAX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BCAX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BCAX Stock dropped -6.17% Today — RQD Quant Desk Flash
Bicara Therapeutics Inc. (BCAX) dropped -6.17% to $9.13, trading at 3% of its 52-week range ($8.36 – $30.99). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($8.36 – $30.99) with RSI-14 at 21.5 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $9.13 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BCAX Headlines & Catalysts
MARKET WIRETradingView • 11h ago
BCAX Stock Price and Chart — NASDAQ:BCAXTradingView report covering Bicara Therapeutics Inc. (BCAX) market action, institutional positioning, and fundamental catalysts.
RISK WATCHInvesting.com • 14h ago
Goldman Sachs downgrades Bicara Therapeutics stock rating to sellInvesting.com report covering Bicara Therapeutics Inc. (BCAX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 17h ago
Wedbush Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)The Globe and Mail report covering Bicara Therapeutics Inc. (BCAX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMoomoo • 20h ago
BMO Capital Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $35Moomoo report covering Bicara Therapeutics Inc. (BCAX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 23h ago
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance report covering Bicara Therapeutics Inc. (BCAX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.marketscreener.com • 1d ago
Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ETwww.marketscreener.com report covering Bicara Therapeutics Inc. (BCAX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETrefis • 1d ago
Market Movers | Winners: AXGN, KIDS, PRME | Losers: BCAX, INBX, FFIVTrefis report covering Bicara Therapeutics Inc. (BCAX) market action, institutional positioning, and fundamental catalysts.
RISK WATCHBenzinga • 3d ago
Goldman Sachs Downgrades Bicara Therapeutics to Sell, Lowers Price Target to $8Goldman Sachs analyst Richard Law downgrades Bicara Therapeutics (NASDAQ:BCAX) from Neutral to Sell and lowers the price target from $20 to $8.
MARKET WIREBenzinga • 4d ago
Wedbush Maintains Outperform on Bicara Therapeutics, Lowers Price Target to $24Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and lowers the price target from $33 to $24.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BCAX)
- ✓Walkthrough of BCAX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BCAX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -59.82%▼ SUPPORT BREAKDOWN
2026-11-02O $9.76H $9.76L $9.13C $9.13VOL 3.20M
RES: $17.30SUP: $12.97SMA50: $19.46SMA200: $21.17
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BCAX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BCAX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BCAX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BCAX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BCAX)
Health Care Rank #842 of 1016
⚔️ OLMA vs BCAX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BCAX vs. OLMA, ABUS, LXRX, IMMX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Bicara Therapeutics Inc. (BCAX) ranks #842 by composite RQD confidence (30/100, grade E) and #413 by equity capitalization ($643.9M). Within this direct 5-issuer industry benchmark cohort, BCAX leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. OLMA currently holds the highest overall quantitative score in the immediate peer group at 31/100 (E) compared with BCAX at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BCAX
ACTIVE
Bicara Therapeutics Inc. | E | 30/100 | — | — | -35.0% | -6.17% | $643.9M | Benchmark Subject |
| OLMA Olema Pharmaceuticals Inc. | E | 31/100 | — | — | -32.8% | -4.50% | $641.4M | /olma-vs-bcax → |
| ABUS Arbutus Biopharma Corporation | E | 18/100 | — | — | -35.0% | -1.64% | $656.0M | /abus-vs-bcax → |
| LXRX Lexicon Pharmaceuticals Inc. | E | 27/100 | — | 96.0% | -31.5% | -4.05% | $658.5M | /lxrx-vs-bcax → |
| IMMX Immix Biopharma Inc. | E | 29/100 | — | — | -35.0% | -3.76% | $661.6M | /immx-vs-bcax → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002023658In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bicara Therapeutics Inc. (BCAX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$137.9M, operating cash flow of -$106.8M, and free cash flow of -$107.1M (-43.2% YoY). On the balance sheet, BCAX closed FY2025 with $431.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$137.9M | -$106.8M | -$107.1M | $431.0M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$68.0M | -$74.8M | -$74.8M | $510.0M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$52.0M | -$45.6M | -$45.6M | — | — |
3. BCAX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BCAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Bicara Therapeutics Inc. (NASDAQ: BCAX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $9.13 (-6.17% 1D, market cap $643.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BCAX ranks #842 in composite RQD confidence.
How does BCAX compare to OLMA and ABUS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BCAX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OLMA (Olema Pharmaceuticals Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -32.8%, cap $641.4M) and ABUS (Arbutus Biopharma Corporation) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $656.0M). Among the 5-stock peer group, BCAX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BCAX?
Per BCAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002023658), Bicara Therapeutics Inc. generated $0 in revenue, -$137.9M in net income, and -$107.1M in free cash flow against $431.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BCAX trading relative to its 50-day, 200-day, and 52-week technical levels?
BCAX last traded at $9.13 (-6.17% on volume of 4,196,028 shares), positioning the stock -53.08% below its 50-day simple moving average ($19.46) and -56.87% below its 200-day simple moving average ($21.17). Across its 52-week range of $8.36 to $30.99, BCAX sits at the 3.4% percentile with a 14-day RSI of 21.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($7.99 to $10.27).
BCAX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BCAX stock moving today?
Why BCAX Stock dropped -6.17% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 30/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
BCAX — Bicara Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:34:14Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, BCAX scores 30 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -35%; FCF yield -16.64%), Whale 13F Flow at 4/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 5/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). The weakest pillars are Insider Conviction and Whale Flow, while the Balance Sheet pillar scores highest but still only halfway. For a prospective investor, the cash engine metrics are the central concern: negative ROIC and negative FCF yield indicate the business is consuming capital rather than generating it, so any upside case depends on future value not yet visible in reported results. The valuation tradeoff is that the stock trades at a price of 9.73 with no earnings-based multiple available in source data to anchor it. Upside drivers would need to come from catalysts outside current cash generation, and the rating frames that as elevated risk rather than a reason to act.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-155.6M | $-137.9M | N/A | $-107.1M | $96.7M | N/A |
| FY 2024 | $0.0M | $-82.4M | $-68.0M | N/A | $-74.8M | $489.7M | N/A |
| FY 2023 | $0.0M | $-39.9M | $-52.0M | N/A | $-45.6M | N/A | N/A |
Per the SEC financials, operating losses widened from $-39.9M in FY 2023 to $-155.6M in FY 2025, and reported cash fell from $489.7M in FY 2024 to $96.7M in FY 2025. Gross, operating, and net margins are each listed as 0%, and ROIC is -35% per the market data. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Debt is not reported in the financial periods provided.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the catalysts include a Yahoo Finance piece titled "Bicara Therapeutics (BCAX) Stock May Look Overvalued On Book Value" (YELLOW), a TradingView stock page (YELLOW), and a Goldman Sachs downgrade to sell reported by Investing.com (RED, flagged RISK WATCH). Wedbush's buy rating (YELLOW) and a BMO Capital buy rating with a $35 target (YELLOW) are also reported. A Yahoo Finance item covers inducement grants under Nasdaq Listing Rule 5635(c)(4) (YELLOW). The news feed contains mixed analyst signals, with one sell-side downgrade flagged as risk and two buy ratings. Per the Butterfly Supply-Chain Graph, no proprietary signals or supply-chain links are present.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE and there are no butterfly links. Upstream and downstream dependencies are not available in source data. Sector correlations are not available in source data beyond the stated beta of 1.0. A prospective investor should watch for any disclosure of partners, licensors, or manufacturing dependencies, none of which appear in the provided data.
Open Questions
- What are the company's products, pipeline stage, and revenue model, given reported revenue of $0.0M in every period?
- What caused the cash balance to decline from $489.7M to $96.7M between FY 2024 and FY 2025, and what is the remaining runway at the FY 2025 FCF burn rate of $-107.1M?
- What is the current debt position, since the debt field is N/A across all periods?
- What drove the Goldman Sachs downgrade and what is the basis for the differing buy ratings from Wedbush and BMO Capital?
- What are the terms and scale of the inducement grants disclosed under Nasdaq Listing Rule 5635(c)(4)?
BCAX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Bicara Therapeutics Inc. (BCAX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 8h ago
Bicara Therapeutics (BCAX) Stock May Look Overvalued On Book Value Yahoo Finance report covering Bicara Therapeutics Inc. (BCAX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 11h ago
BCAX Stock Price and Chart — NASDAQ:BCAX TradingView report covering Bicara Therapeutics Inc. (BCAX) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Investing.com • 14h ago
Goldman Sachs downgrades Bicara Therapeutics stock rating to sell Investing.com report covering Bicara Therapeutics Inc. (BCAX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 17h ago
Wedbush Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX) The Globe and Mail report covering Bicara Therapeutics Inc. (BCAX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 20h ago
BMO Capital Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $35 Moomoo report covering Bicara Therapeutics Inc. (BCAX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 23h ago
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance report covering Bicara Therapeutics Inc. (BCAX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.marketscreener.com • 1d ago
Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET www.marketscreener.com report covering Bicara Therapeutics Inc. (BCAX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Trefis • 1d ago
Market Movers | Winners: AXGN, KIDS, PRME | Losers: BCAX, INBX, FFIV Trefis report covering Bicara Therapeutics Inc. (BCAX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
BCAX Bull vs. Bear Conversation Board — What's Your Call at $9.13?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BCAX 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $8.56 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is BCAX (E • RQD 30/100) a Buy at $9.73?
Welcome to the BCAX (Bicara Therapeutics Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $8.08 (-17.0%)
Spot @ $9.73 Pump the brakes on BCAX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on BCAX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Bicara Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $11.19 (+15.0%)
Spot @ $9.73 BCAX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on BCAX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $9.73 (52-wk range $8.36 - $30.99), any beat on forward guidance forces shorts and underweight funds to chase.